Your session is about to expire
← Back to Search
Octreotide Depot for Neuroendocrine Tumors (SORENTO Trial)
SORENTO Trial Summary
This trial will compare the effectiveness and safety of a new drug (CAM2029) to existing treatments (octreotide LAR or lanreotide ATG) in patients with advanced, well-differentiated GEP-NET. If the new drug is not effective, patients may receive intensified treatment in the open-label extension part of the study.
SORENTO Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSORENTO Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SORENTO Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer is advanced, cannot be surgically removed, and started in my gastrointestinal tract.My cancer has spread to my brain.I can take care of myself and am up and about more than half of my waking hours.I have a tumor visible on scans that responds to a specific hormone.I have not had specific artery treatments for my NET in the last year.My cancer is a type that started in the digestive system and cannot be surgically removed.I am 18 years old or older.I have been on long-acting SSAs for over 6 months.I have a tumor visible on scans that responds to a specific hormone.I have had radioligand therapy before.My carcinoid symptoms haven't improved with standard treatments.My cancer has worsened despite treatment.I have had more than one round of specific treatments for my neuroendocrine tumor.
- Group 1: CAM2029
- Group 2: Octreotide LAR or lanreotide ATG
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many applicants will be able to join this research project?
"The sponsor, Camurus AB, needs to recruit 300 individuals who match the clinical trial's inclusion criteria from various sites including East Jefferson General Hospital in Metairie, Louisiana and Mayo Clinic Rochester in Rochester, Minnesota."
What other medical studies have included CAM2029 as a variable?
"First studied in 1997 at Vanderbilt University's Autonomic Dysfunction Center, CAM2029 has had a total of 137 completed studies as of today. However, there are still 21 ongoing studies recruiting patients. The majority of these trials are taking place in Metairie, Louisiana."
Can you summarize the risks associated with CAM2029?
"CAM2029 rates a 3 on our Power scale due to being in Phase 3 trials--meaning that, while there is data supporting efficacy, there are multiple rounds of data affirming safety."
Are there any vacancies left for this research project?
"Yes, this trial is still looking for participants. It was originally posted on October 22nd, 2021 and the most recent update was on October 21st, 2022."
What are the conditions that doctors usually prescribe CAM2029 for?
"While most often used to treat neoplasm metastasis, CAM2029 can also be effective in palliating symptoms associated with octreotide, vasoactive intestinal peptide tumors, and advance directives."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger